CD Bioparticles' magnetic bead liquid biopsy platform development is a cutting-edge, integrated service designed to enable high-sensitivity enrichment and purification of low-abundance circulating biomarkers—including circulating tumor cells (CTCs), cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA), exosomes, and circulating proteins. By fusing our proprietary magnetic bead technology with liquid biopsy workflow optimization, we deliver customized platforms that solve core pain points of sample processing, supporting non-invasive diagnosis, real-time disease monitoring, and precision medicine translation for academic labs, biotech companies, and clinical diagnostic developers.
Introductions
Liquid biopsy has revolutionized modern healthcare by enabling non-invasive, real-time assessment of disease status—eliminating the need for invasive tissue biopsies while providing dynamic insights into disease progression, treatment response, and drug resistance. Its core relies on capturing and analyzing rare circulating biomarkers from bodily fluids (blood, urine, cerebrospinal fluid), but traditional liquid biopsy workflows face critical limitations: extremely low biomarker abundance, high background interference from non-target cells/biomolecules, and risk of target degradation or loss during processing. Magnetic bead-mediated technology has become the gold standard for addressing these challenges, offering unparalleled specificity, enrichment efficiency, and gentle sample handling. As a global leader in functional magnetic particles and bioassay solutions, CD Bioparticles leverages years of expertise in magnetic material synthesis, bioconjugation, and clinical sample processing to develop end-to-end liquid biopsy platforms. Our services are tailored to diverse biomarker types, sample matrices, and research/clinical goals, ensuring compatibility with mainstream downstream detection technologies and compliance with clinical translational standards.
Technology Overview
Our platform is built on three synergistic technical pillars, optimized to unlock the full potential of liquid biopsy through high-performance biomarker enrichment and purification:
1. Biomarker-Specific Functional Magnetic Beads
- Proprietary magnetic particles with controlled size (50 nm–5 μm), uniform magnetic responsiveness, and low non-specific binding—critical for capturing rare targets.
- Customizable surface modifications (antibody-coupled, aptamer-functionalized, oligonucleotide-conjugated, or protein A/G-coated) to target unique biomarkers:
- CTCs: Ligands for epithelial markers (EpCAM, HER2) or stem cell markers (CD44, CD133).
- ctDNA/cfDNA: Magnetic beads modified with capture probes or chromatin-binding proteins for sequence-specific or universal enrichment.
- Exosomes: Ligands for surface markers (CD63, CD81) or target cargo proteins/nucleic acids.
- Biocompatible formulations that preserve biomarker integrity (cell viability for CTCs, nucleic acid stability for ctDNA/exosomes) during processing.
2. High-Efficiency Enrichment & Purification Technology
- Optimized binding kinetics between magnetic beads and biomarkers, achieving enrichment factors of 100–1000x and target recovery rates >85%.
- Gentle magnetic separation protocols (low magnetic field strength, short processing time) to minimize mechanical stress and biomarker degradation.
- Multi-step washing workflows designed to reduce background interference (e.g., leukocyte depletion for CTCs, protein/nucleic acid contaminants for ctDNA), ensuring target purity >95%.
3. Downstream Detection Compatibility
- Seamless integration with mainstream liquid biopsy detection technologies: next-generation sequencing (NGS), quantitative PCR (qPCR), digital PCR (dPCR), flow cytometry, and mass spectrometry.
- Customizable workflow design for diverse sample volumes (100 μL–10 mL) and throughput needs (lab-scale to high-throughput automation with 96/384-well plates).
- Compatibility with various sample matrices (peripheral blood, plasma, serum, urine, ascites) and pre-processing steps (cell lysis, exosome isolation, cfDNA extraction).
Our Services
We provide comprehensive development services to create bespoke liquid biopsy solutions:
- Custom Assay Development: Design and optimization of complete workflows for specific cancer types and clinical applications.
- Bead Functionalization & Optimization: Selection, modification, and validation of magnetic beads for maximum capture efficiency and minimal non-specific binding.
- Platform Integration & Automation: Development of automated systems for high-throughput processing, reducing manual intervention and improving reproducibility.
- Analytical Validation: Comprehensive testing of sensitivity, specificity, linearity, and reproducibility against clinical standards.
- Regulatory Support: Assistance with platform documentation and validation for clinical application and regulatory submissions.
Applications
Our magnetic bead liquid biopsy platforms enable advancements in multiple clinical and research areas:
- Early Cancer Detection: Sensitive identification of tumor-derived biomarkers in asymptomatic individuals.
- Treatment Monitoring: Real-time assessment of therapy response through dynamic biomarker quantification.
- Minimal Residual Disease Detection: Ultra-sensitive monitoring for recurrence following treatment.
- Therapeutic Target Identification: Isolation of biomarkers for guiding targeted therapy selection.
- Cancer Evolution Studies: Longitudinal monitoring of tumor heterogeneity and resistance mechanisms.
Our Process
Our approach is highly collaborative, ensuring the final product meets your exact specifications:
Synthesis and functionalization
Characterization and validation
Quality assurance and delivery
Our Advantages
Deep Technical Expertise
CD Bioparticles boasts decades of experience in magnetic particle synthesis, surface modification, and bioconjugation. Our proprietary technologies and in-house R&D capabilities enable us to develop high-performance magnetic beads with tailored properties.
End-to-End Capabilities
We recognize that every client's needs are unique. Our services cover full customization—from magnetic bead design and ligand conjugation to workflow optimization and platform integration—adapting to specific target proteins, sample types, and experimental requirements.
Rigorous Quality Assurance
All our magnetic beads and platform components undergo strict quality control (QC) at every stage—from raw material selection and synthesis to conjugation and final validation. Our commitment to quality guarantees that you receive a reliable, robust platform that accelerates your project progress.
CD Bioparticles' magnetic bead liquid biopsy platform development addresses the core bottlenecks of non-invasive disease detection by delivering high-sensitivity, specific, and reliable biomarker enrichment solutions. Our integration of proprietary magnetic bead technology, workflow optimization, and regulatory alignment empowers you to advance precision medicine, accelerate clinical trials, and bring transformative liquid biopsy diagnostics to patients. We partner closely with you to understand your unique challenges, refine protocols, and ensure the platform meets your performance and regulatory needs. With our technical leadership and customer-centric approach, you can streamline liquid biopsy workflows, reduce experimental variability, and unlock actionable insights from rare circulating biomarkers.
